Telomir Pharmaceuticals (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced the peer-reviewed publication of preclinical research showing its lead candidate, Telomir-Zn, significantly improved visual function, restored retinal structure, and reduced mitochondrial oxidative stress in a model of age-related macular degeneration (AMD). The study, published in the International Journal of Molecular Sciences, also found that treatment was associated with restoration of altered DNA methylation patterns and a dose-dependent increase in relative telomeric DNA content toward levels observed in healthy animals.
These findings are important because AMD is a leading cause of vision loss among older adults, and current treatment options are limited, particularly for the dry form of the disease. The preclinical results suggest a potential new mechanism of action that could address both functional and structural damage in the retina. Moreover, the study provides a potential mechanistic link between intracellular metal modulation and epigenetic regulation, as Telomir-Zn reduced intracellular labile iron and inhibited iron-dependent Jumonji C histone demethylases. This could open new avenues for treating diseases where epigenetic dysregulation and oxidative stress play a role.
Despite the promising preclinical data in AMD, Telomir said its clinical development remains focused on oncology. Telomir-Zn is advancing under an FDA-cleared Investigational New Drug application for a Phase 1/2 trial in patients with advanced or metastatic triple-negative breast cancer. This strategic focus highlights the company's commitment to addressing significant unmet needs in cancer, while the AMD findings may represent an additional opportunity for the compound.
For investors and industry observers, the publication in a peer-reviewed journal adds scientific credibility to Telomir's platform and could increase interest in the company's pipeline. The news may also impact the broader biotechnology sector by demonstrating the potential of epigenetic and metabolic approaches in treating age-related diseases. As the company progresses its oncology program, the AMD data could provide further validation of Telomir-Zn's mechanism and support future development in other indications.
To view the full press release, visit https://ibn.fm/iUtFx. The latest news and updates relating to TELO are available in the company's newsroom at https://ibn.fm/TELO. BioMedWire, a specialized communications platform focused on biotechnology and life sciences, is one of 75+ brands within the Dynamic Brand Portfolio at IBN. Through InvestorWire, it provides wire solutions and editorial syndication to 5,000+ outlets, along with press release enhancement and social media distribution to millions of followers. For more information, visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
